CBIO

Crescent Biopharma, Inc.

$17.09 +0.01 (+0.06%) At close · Jul 2

Market Cap

$471.25M

27,571,935

Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.

Date	Insider	Role	Type	Shares	Price	Value	After
2026-06-22	Bispham Barbara Harlin	See Remarks	Sell	1,218	$17.99	$21,912	19,330
2026-06-22	Im Ellie Eunkyung	Chief Medical Officer	Sell	1,219	$17.99	$21,930	22,069
2026-06-22	Scalzo Richard William	Chief Financial Officer	Sell	1,112	$17.99	$20,005	20,298
2026-06-22	McNeill Jonathan	President and COO	Sell	20,549	$17.99	$369,677	139,158
2026-06-22	Lynch Ryan	See Remarks	Sell	465	$17.99	$8,365	13,871
2026-06-22	Pinkas Jan	Chief Scientific Officer	Sell	1,288	$17.99	$23,171	22,239
2026-06-22	Brumm Joshua T	Director, Chief Executive Officer	Sell	42,305	$17.99	$761,067	281,212
2026-06-02	Lubner David Charles	Director	Award	11,050	—	—	11,050
2026-06-02	Balcom Alexandra	Chief Financial Officer	Award	11,050	—	—	11,050
2026-06-02	Moran Susan	Director	Award	11,050	—	—	11,050
2026-06-02	Fairmount Funds Management LLC	Director	Award	11,050	—	—	11,050
2026-06-02	Violin Jonathan	Director	Award	11,050	—	—	11,050
2025-12-15	Brumm Joshua T	Director, Chief Executive Officer	Award	45,117	—	—	313,517
2025-12-15	McNeill Jonathan	President and COO	Award	19,507	—	—	153,707
2025-12-15	Pinkas Jan	Chief Scientific Officer	Award	70,025	—	—	70,025
2025-12-15	Scalzo Richard William	Chief Financial Officer	Award	57,688	—	—	57,688
2025-12-15	Scalzo Richard William	Chief Financial Officer	Award	14,422	—	—	14,422
2025-12-15	Doughty Christopher Grant	Chief Business Officer	Award	8,000	—	—	62,194
2025-12-15	McNeill Jonathan	President and COO	Award	6,000	—	—	159,707
2025-12-15	Im Ellie Eunkyung	Chief Medical Officer	Award	16,298	—	—	16,298
2025-12-15	Doughty Christopher Grant	Chief Business Officer	Award	14,714	—	—	54,194
2025-12-15	Im Ellie Eunkyung	Chief Medical Officer	Award	5,000	—	—	21,298
2025-12-15	Brumm Joshua T	Director, Chief Executive Officer	Award	180,467	—	—	180,467
2025-12-15	Bispham Barbara Harlin	See Remarks	Award	12,422	—	—	12,422
2025-12-15	Lynch Ryan	See Remarks	Award	8,378	—	—	8,378
2025-12-15	Scalzo Richard William	Chief Financial Officer	Award	5,000	—	—	19,422
2025-12-15	McNeill Jonathan	President and COO	Award	78,029	—	—	78,029
2025-12-15	Bispham Barbara Harlin	See Remarks	Award	6,000	—	—	18,422
2025-12-15	Brumm Joshua T	Director, Chief Executive Officer	Award	10,000	—	—	323,517
2025-12-15	Im Ellie Eunkyung	Chief Medical Officer	Award	65,190	—	—	65,190
2025-12-15	Pinkas Jan	Chief Scientific Officer	Award	5,000	—	—	22,507
2025-12-15	Lynch Ryan	See Remarks	Award	4,000	—	—	12,378
2025-12-15	Doughty Christopher Grant	Chief Business Officer	Award	58,855	—	—	58,855
2025-12-15	Bispham Barbara Harlin	See Remarks	Award	72,185	—	—	72,185
2025-12-15	Lynch Ryan	See Remarks	Award	33,512	—	—	33,512
2025-12-15	Pinkas Jan	Chief Scientific Officer	Award	17,507	—	—	17,507
2025-12-08	McNeill Jonathan	President and COO	Award	172,836	—	—	172,836
2025-12-08	Brumm Joshua T	Director, Chief Executive Officer	Award	345,672	—	—	345,672
2025-12-04	Fairmount Funds Management LLC	Director	Buy	131,434	$13.41	$1,762,399	1,768,140
2025-12-04	Fairmount Funds Management LLC	Director	Buy	1,360,000	$13.41	$18,237,600	2,747,866
2025-07-16	Pinkas Jan	Chief Scientific Officer	Award	142,474	—	—	142,474
2025-07-07	Pinkas Jan	Chief Scientific Officer	Other	0	—	—	0
2025-06-23	Balcom Alexandra	Chief Financial Officer	Award	9,023	—	—	9,023
2025-06-23	Lubner David Charles	Director	Award	9,023	—	—	9,023
2025-06-23	Fairmount Funds Management LLC	Director	Award	9,023	—	—	9,023
2025-06-23	Moran Susan	Director	Award	9,023	—	—	9,023
2025-06-23	Violin Jonathan	Director	Award	9,023	—	—	9,023
2025-06-13	BVF PARTNERS L P/IL	10% Owner	Other	556,617	—	—	593,740
2025-06-13	BVF PARTNERS L P/IL	10% Owner	Other	56,079	—	—	62,383
2025-06-13	BVF PARTNERS L P/IL	10% Owner	Other	657,308	—	—	707,116

Showing 1–50 of 200 transactions

Key facts CIK 1253689 CUSIP G2545C104 Visit website Investor relations